Zacks' Senior Life Sciences Analyst John Vandermosten initiates on #ActiniumPharmaceuticals with a $4.00 price target.
youtube.com/shorts/Gh-GB...
Initiation: tinyurl.com/bdj6rjtm
$ATNM #NuclearMedicine #Radiopharmaceuticals #Oncology #AML #TargetedRadiotherapy #Biotech #CancerResearch